Analysts await Apricus Biosciences, Inc (NASDAQ:APRI) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.09 EPS, up 44.44% or $0.04 from last year’s $-0.13 per share.

At the moment 3 analysts are watching Apricus Biosciences, Inc (NASDAQ:APRI), 0 rate it “Buy”, 2 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 3 analysts have a mean sales target of 1.65 million. For the quarter ending Sep-16, 3 analysts have a mean sales target of 1.71 million whilst for the year ending Dec-16, 3 analysts have a mean target of 6.69 million.

In terms of earnings per share, 3 analysts have a -0.06 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 3 analysts have a -0.07 EPS mean target and for the quarter ending Sep-16 there are 3 estimates of -0.25 EPS.

The biggest institutional shareholders in Apricus Biosciences, Inc include Sarissa Capital Management LP which owns 8 million shares in the company valued at $7.75 million. SGM Holdings Corp. is the second biggest holder with 2 million shares currently valued at 3.15 million whilst Vanguard Group Inc has 1 million shares valued at 1.43 million.

Total shares held by institutions as of the most recent company filings are 12,973,331 with a reported 1,348,756 bought and 544,754 sold. These holdings make up 21% of the company’s outstanding shares.

Currently insiders hold 11,990,802 shares in the business which makes up 19.41% of shares. The biggest holder currently is Mr. Jacob May who owns 5,714,630 shares (9.25% of those outstanding), whilst Dr. Bassam B. Damaj,PhD holds 1,611,747 (2.61% of shares outstanding) and Y. Joseph Mo,PhD holds 1,556,429 (2.52% of shares outstanding).

The stock decreased 2.3617% or $0.0111 during the last trading session, hitting $0.5815. Apricus Biosciences, Inc (NASDAQ:APRI) has fallen 115.22% over the past 6 months and is downtrending.